#	Pagina
attuale pagina	/open-h2020/projects/206567/index.html

Opendata, web and dolomites

NEW DEAL SIGNED

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NEW DEAL project word cloud

Explore the words cloud of the NEW DEAL project. It provides you a very rough idea of what is the project "NEW DEAL" about.

efficacy capsules cells immunology safety diseases locally polymeric oral inhibition therapy successful drawbacks transit combining deal expertise good jak3 antibodies nanostructured selective carriers validated nanomedicine inflamed experts immune avenues solution historic carefully manner ibd administration inflammatory tolerability submission generate background bowel stage gastroenterology sirna gut lipid progress pharma brings inhibit people mediated proven therapies manufacturing smes evaluation clinical jak plasma disorders transport nanosafety medicinal membrane safer mucus intestinal therapeutic innovative mean radical young translation preclinical designed thanks clinics barrier gi nanotherapeutics patients convenience biology immunogenicity protecting scientists tract industrial company rnai plan regulatory transfer

Project "NEW DEAL" data sheet

The following table provides information about the project.

Coordinator	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 website: www.cea.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.newdeal-project.eu
Total cost	5˙999˙178 €
EC max contribution	5˙999˙178 € (100%)
Programme	1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-NMBP-2016-two-stage
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 website: www.cea.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS 15)	coordinator	1˙915˙936.00
2	CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER Organization address address: CALLE ROSSELLO 149 PUERTA BJS city: BARCELONA postcode: 8036 website: http://www.idibaps.org/en_index.html contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	774˙723.00
3	NANOIMMUNOTECH SL NANOIMMUNOTECH SL Organization address address: EDIFICIO CITEXVI C FONTE DAS ABELLE SN CAMPUS UNIVERSITARIO DE VIGO city: VIGO PONTEVEDRA postcode: 36310 website: www.nanoimmunotech.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VIGO PONTEVEDRA)	participant	506˙813.00
4	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	475˙258.00
5	PRODIGEST PRODIGEST Organization address address: TECHNOLOGIEPARK 3 city: GENT ZWIJNAARDE postcode: 9052 website: www.prodigest.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GENT ZWIJNAARDE)	participant	463˙343.00
6	LABORATOIRES MAYOLY SPINDLER LABORATOIRES MAYOLY SPINDLER Organization address address: 6 AVENUE DE L'EUROPE city: CHATOU postcode: 78400 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (CHATOU)	participant	448˙750.00
7	HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Organization address address: INHOFFENSTRASSE 7 city: BRAUNSCHWEIG postcode: 38124 website: www.helmholtz-hzi.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BRAUNSCHWEIG)	participant	384˙965.00
8	SEPS PHARMA SEPS PHARMA Organization address address: AGORALAAN ABIS city: DIEPENBEEK postcode: 3590 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (DIEPENBEEK)	participant	373˙125.00
9	EUROPEAN RESEARCH SERVICES GMBH EUROPEAN RESEARCH SERVICES GMBH Organization address address: ROENTGENSTRASSE 19 city: MUENSTER postcode: 48149 website: www.european-research-services.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENSTER)	participant	233˙337.00
10	SCIENSEED SL SCIENSEED SL Organization address address: CALLE ARTE 3 5/A city: MADRID postcode: 28033 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	190˙288.00
11	ALAN BOYD CONSULTANTS LIMITED ALAN BOYD CONSULTANTS LIMITED Organization address address: ELECTRA HOUSE, CREWE BUSINESS PARK city: CREWE postcode: CW1 6GL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CREWE)	participant	188˙750.00
12	SPARKS & CO SPARKS & CO Organization address address: 66 AVENUE DES CHAMPS ELYSEES ESPACE 41 city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	43˙886.00

Map

Project objective

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.

Deliverables

List of deliverables.
Basic communication tools	Websites, patent fillings, videos etc.	2019-05-14 12:33:11

Take a look to the deliverables list in detail: detailed list of NEW DEAL deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Benedikt C. Huck, Olga Hartwig, Alexander Biehl, Konrad Schwarzkopf, Christian Wagner, Brigitta Loretz, Xabier Murgia, Claus-Michael Lehr Macro- and Microrheological Properties of Mucus Surrogates in Comparison to Native Intestinal and Pulmonary Mucus published pages: 3504-3512, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.9b00780	Biomacromolecules 20/9	2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEW DEAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEW DEAL" are provided by the European Opendata Portal: CORDIS opendata.